HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

[1]  C. Guttmann,et al.  HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study , 2011, Genes and Immunity.

[2]  M. Ramanathan,et al.  Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients , 2011, PloS one.

[3]  I. James,et al.  Spinal cord involvement in multiple sclerosis: A correlative MRI and high-resolution HLA-DRB1 genotyping study , 2011, Journal of the Neurological Sciences.

[4]  B. C. Healy,et al.  HLA B*44 , 2010, Neurology.

[5]  I. James,et al.  Influence of HLA-DRB1 allele heterogeneity on disease risk and clinical course in a West Australian MS cohort: a high-resolution genotyping study , 2010, Multiple sclerosis.

[6]  F. Barkhof,et al.  MRI criteria for MS in patients with clinically isolated syndromes , 2010, Neurology.

[7]  J. Lünemann,et al.  Elevated Epstein–Barr virus‐encoded nuclear antigen‐1 immune responses predict conversion to multiple sclerosis , 2010, Annals of neurology.

[8]  M Ramanathan,et al.  Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. , 2009, Brain : a journal of neurology.

[9]  F Fazekas,et al.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[10]  M. Ramanathan,et al.  Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis , 2009, Neurology.

[11]  M. Ramanathan,et al.  Gene–environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis , 2009, Journal of Neuroimmunology.

[12]  Michael R. Johnson,et al.  Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.

[13]  S J Nelson,et al.  Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. , 2009, Brain : a journal of neurology.

[14]  A. Lutterotti,et al.  Smoking is a risk factor for early conversion to clinically definite multiple sclerosis , 2008, Multiple sclerosis.

[15]  A. Sadovnick,et al.  Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis , 2008, Journal of Neurology.

[16]  N. Risch,et al.  An extremes of outcome strategy provides evidence for multiple sclerosis severity being determined by alleles at the HLA-DRB1 locus , 2008 .

[17]  T. Hudson,et al.  An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus , 2007, Proceedings of the National Academy of Sciences.

[18]  M. Ramanathan,et al.  Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. , 2007, Human molecular genetics.

[19]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[20]  A. Minagar,et al.  HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. , 2007, International review of neurobiology.

[21]  E. Frohman,et al.  Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.

[22]  Massimo Filippi,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management , 2005, The Lancet Neurology.

[23]  A. Thompson,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.

[24]  A. Kheradvar,et al.  Optic neuritis, multiple sclerosis and human leukocyte antigen: results of a 4‐year follow‐up study , 2005, European journal of neurology.

[25]  R. Zivadinov,et al.  HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis , 2003, Journal of Neurology.

[26]  R. Rudick,et al.  Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS , 2001, Neurology.

[27]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[28]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[29]  S. Cole,et al.  Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS , 2000, Neurology.

[30]  B. Jørgensen,et al.  Dispersion models and longitudinal data analysis. , 1999, Statistics in medicine.

[31]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[32]  J. Hillert,et al.  Optic neuritis , 1998, Neurology.

[33]  D. Miller,et al.  The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. , 1993, Brain : a journal of neurology.

[34]  L. Jacobs,et al.  Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study. , 1986, Archives of neurology.